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Abstract
Pharmacologic reversal of serious or intolerable side effects (SISE) from vasodilator stress is an important safety and
comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline,
recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This
information statement provides background and recommendations addressing indications for vasodilator reversal,
timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations
for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols.
Overview
The purpose of this document is to provide cardiac imaging
specialists performing vasodilator stress testing with specific
recommendations regarding options for the reversal of
vasodilator stress. The timeliness of this document is
associated with recurrent shortages of aminophylline, which
has been used in most laboratories for reversal of serious
and intolerable side effects (SISE) from vasodilator stress.
This information serves as a summary of expert opinion
on this topic developed by the American Society of Nuclear
Cardiology (ASNC) and endorsed by the Society for
Cardiovascular Magnetic Resonance (SCMR). This docu-
ment covers general indications for reversal of SISE from
vasodilator stress, the standard reversal procedure using
intravenous (IV) aminophylline, and alternative options
based on evidence and expert opinion for effective
and safe reversal of SISE from vasodilator stress during
pharmacologic stress myocardial perfusion imaging (MPI)
with single photon emission computed tomography
(SPECT), positron emission tomography (PET), or
cardiovascular magnetic resonance (CMR).
Indications for vasodilator stress reversal
ASNC 2016 imaging guidelines for SPECT nuclear cardi-
ology procedures[1] support using aminophylline for
reversing the effects of vasodilator stress testing with
adenosine, regadenoson and dipyridamole when SISE are
encountered. The guidelines reflect evidence that most
vasodilator stress-related adverse effects are self-limiting
and do not require reversal. Serious adverse effects can be
effectively aborted with IV administration of aminophyl-
line, a xanthine derivative and a nonselective adenosine
receptor antagonist [2], with the exception of seizures.
Intravenous lorazepam should be the first-line interven-
tion for seizures and methylxanthine use is not recom-
mended for reversal of adenosine or regadenoson effects
under these circumstances because of the concern for
possible lowering of the seizure threshold and potential
risk of exacerbating seizures [3], based on limited evidence
and the preponderance of expert opinion.
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Based on the 2016 guidelines[1], indications for rever-
sal of vasodilator stress using IV aminophylline (50 to
250 mg intravenously at least 1 min after the tracer
injection) include the following:
1. Severe hypotension (systolic blood pressure (BP)
≤80 mmHg) or symptomatic hypotension;
2. Development of symptomatic, persistent Mobitz II
second degree or complete heart block;
3. Significant cardiac arrhythmia (e.g. ventricular
tachycardia);
4. Wheezing;
5. Severe chest pain associated with ST depression of
2 mm or greater, or ST elevation of 1 mm or
greater;
6. Signs of poor perfusion (pallor, cyanosis, cold or
clammy skin);
7. Intolerable symptoms such as nausea, vomiting, or
abdominal pain.
It is important for clinicians to identify patients at
risk for SISE who may need prompt reversal of vaso-
dilator stress agent. Those at risk include patients with
borderline low systolic BP (< 100 mmHg), baseline 1st
or 2nd degree atrioventricular block, reactive airway
disease, or acute coronary syndrome presentation [4].
Patients with end-stage renal disease tend to have
higher frequency of regadenoson-induced gastrointes-
tinal side effects [5, 6].
For CMR stress with regadenoson, in addition to SISE,
pharmacologic reversal may be required for a minority of
examinations (< 25%) in which rest perfusion imaging is
needed for artifact differentiation observed on stress
imaging. In such a case, given the half-life of regadenoson
and the short window between stress and rest CMR perfu-
sion imaging, vasodilator stress reversal may be deemed
necessary if there is concern for residual drug effect.
Timing of a reversal agent
Few studies have examined how early following radioiso-
tope administration a reversal agent for vasodilator
stress can be administered without influencing the
results of perfusion imaging.
The majority of myocardial uptake of the radioisotope
occurs within 1–2min following the radioisotope injection
[7–10]. Thus, it is important to maintain vasodilator-in-
duced myocardial hyperemic state during this period.
However, if a very serious adverse event were to occur, the
vasodilator should be reversed immediately. If vasodilator
agent reversal occurs in the first minute following radio-
isotope injection, the “stress” perfusion could well be com-
promised. Therefore, following a premature reversal of
vasodilator stress, if myocardial perfusion imaging is
normal or myocardial ischemia is absent in a patient with
high likelihood of ischemic heart disease, the possibility of
a “false-negative” scan should be considered and further
testing with an alternative stress agent (such as dobuta-
mine) should be considered. For stress CMR, a reversal
agent can be given once first-pass stress perfusion images
have been acquired.
Incidence of observed side effects with
vasodilator stress
Based on published evidence, the vasodilator stressor
agents used in current cardiology practice are safe and
have a very low observed rate of serious adverse effects
(Table 1). Mild, easily reversible adverse effects are fre-
quent. Perceived shortness of breath associated with rega-
denoson is commonly seen and does not reflect elevated
pulmonary capillary wedge pressure, but may reflect a
central nervous system effect [11]. Gastrointestinal side
effects are overall mild/transient and are more frequently
observed in patients with end-stage renal failure undergo-
ing regadenoson stress [5, 6].
Table 2 [3] provides more detailed information regard-
ing SISE associated with vasodilator stress agents which
essentially represents a list of indications for the reversal
procedure (with the exception of seizures). As can be
seen from these data, the rate of occurrence of clinical
situations matching the list of indications for reversing
vasodilator stress is very infrequent.
Considering combined evidence of serious adverse
effects of clinically utilized vasodilator agents and actual
guidelines-endorsed indications for aminophylline use, a
nuclear cardiology or CMR laboratory will encounter
occasional cases that require vasodilator stress reversal.
The rate of these cases has not been definitively assessed
but it is certainly less than 10% and may be as low as 1%
based on Tables 1 and 2. With periodic shortage of ami-
nophylline, selective use of reversal agents is a reason-
able alternative to routine use and does not compromise
safety or effectiveness of testing.
Aminophylline-based vasodilator stress reversal:
Clinical and logistical considerations
Despite the data demonstrating that only a fraction of
vasodilator stress studies require a reversal procedure,
present day cardiac imaging laboratories utilize IV
aminophylline much more frequently and with high
regional variability. In different clinical practices in
the US, the proportion of vasodilator stress tests with
aminophylline use ranges from less than 3 to 100%
[12], the latter being in an attempt to prevent any
possible adverse effects of the vasodilator stress.
Randomized controlled trials demonstrate use of ami-
nophylline is safe, well tolerated, and effective in
improving overall patient satisfaction with vasodilator
stress testing, the latter by reducing uncomfortable and
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easily treatable symptoms [13, 14]. In pooled analysis of
two randomized but non-crossover trials including 548
patients, investigators found that perfusion did not
appear to be impacted if aminophylline was adminis-
tered 1.5 min following Tc-99 m tetrofosmin injection
[15]. Until further studies are performed, a delay of 2
or more minutes after tracer injection is prudent if
reversal is indicated. With this delay, if SISE are en-
countered during vasodilator stress, the reversal pro-
cedure should be performed without concern for
altering imaging findings.
To date, we do not have any published evidence whether
routine or “prophylactic” vasodilator stress reversal using
IV aminophylline (or any other reversal agent), regardless
of whether or not a patient develops an adverse reaction, is
clinically beneficial. Such prophylactic use is not included
in the package inserts of regadenoson, adenosine, or dipyr-
idamole. However, it may unnecessarily complicate the per-
formance of vasodilator stress, introduce an intervention
that may affect imaging findings if administered too soon
after tracer injection, and, at least hypothetically, increase
risk due to exposure to an unnecessary medical agent.
Accordingly, this approach is not recommended.
Alternative non-aminophylline based vasodilator
stress reversal protocols
When aminophylline is in short supply but reversal of
SISE from vasodilator stress is indicated, alternative
reversal agents that have been shown to be effective in
this setting should be used.
One such agent is another xanthine derivative, theophyl-
line, which has been reported to reverse adverse
symptoms of the vasodilator stressor agents safely and
effectively. Since aminophylline is a salt that contains
approximately 80% theophylline by weight, lower doses of
theophylline can achieve the same reversal effects. More-
over, due to differences in concentration between ami-
nophylline (25mg/mL) and theophylline (0.8mg/mL), it
becomes impractical to administer more than 50mg of
theophylline as a single dose, equivalent to roughly 60mg
of aminophylline. A total of 5 published series with 215
patients support the use of IV theophylline as a vasodila-
tor stress reversal agent [16]. In the largest such series,
154 patients received theophylline for reversal of dipyrid-
amole; only 11 patients (7%) required a second injection,
and in all cases side effects or frank ischemia from dipyr-
idamole were successfully treated [16].
Table 1 Adverse effects of the vasodilator stressor agents (data derived from 2016 ASNC imaging guidelines for SPECT nuclear
cardiology procedures [1], from Subbiah et al. [19], and from Doukky et al. [20])
Dipyridamole Adenosine Regadenoson
Minor side effects (total) ~ 50% ~ 80% ~ 50%
flushing 3% 35–40% 17%
nonspecific chest pain 20% 25–30% 11%
dyspnea 10% 20% 25%
dizziness 12% 7% 7%
hypotension 5% 5% 5%
nausea 5% 5% 6%
headache 12% 10% 29%
abdominal discomfort 5–10% 5–14% 6–17%
Transient conduction abnormalities:
Overall 2% 8.5% 4%
Transient 2nd degree AVB 1–2% 4% 0.1%
Transient ST depression of ≥1 mm 8% 5–7% 1–2% [20]
Major side effects < 1% < 1% < 1%
Complete AVB < 1% < 1% Rare
Severe (> 2 mm) ST depression < 1% < 1% < 1%
Fatal or nonfatal MI Extremely rare Extremely rare Extremely rare
Stroke Extremely rare Extremely rare Extremely rare
Seizures Rare Rare Rare
Comments Symptoms may last longer
(15–25 min) than with other
vasodilator stressors; Aminophylline
frequently required
Due to a short half-time, most
side effects resolve in a few (< 10)
seconds after discontinuation
of the infusion; Aminophylline
rarely required
Most adverse reactions begin
soon after injection and resolve
within 15 min (headaches may
last up to 30min)
AVB atrioventricular block; MI myocardial infarction
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Another widely available methylxanthine inhibitor of
the adenosine receptors (including adenosine 2A recep-
tors activated by regadenoson) is caffeine. This agent is
administered via either an IV or oral route. Both oral and
IV caffeine were recently compared in a randomized con-
trolled fashion to IV aminophylline by Doran et al.[17]
and were shown to provide rapid and safe reversal of
vasodilator-induced adverse effects during SPECT MPI.
This study evaluated the effect of reversal agents on
patient-reported symptoms in a series of 241 consecutive
patients presenting to the stress laboratory and undergo-
ing regadenoson stress. Patients were randomized to IV
aminophylline, to 60mg of IV caffeine over 3 to 5min, or
to oral caffeine as either regular coffee or diet cola taken
ad lib (estimated 60–160mg oral caffeine, with no exact
dose available). No serious adverse effects of regadenoson
were encountered. Of the 241 patients undergoing regade-
noson stress, 152 (63%) received a reversal agent. Rates of
complete or predominant reversal were 100% with IV ami-
nophylline, 96% with IV caffeine (P=NS vs aminophylline),
and 84% with PO caffeine (P = 0.003 vs IV aminophylline).
Of the 37 patients in the oral caffeine group, 19 assigned
to oral caffeine crossed over to receive IV caffeine based
on concern the symptoms might be too severe for oral
caffeine to be effective [17].
Alternative methods of caffeine administration have also
been used, such as buccal administration, which is
thought to be rapid and well tolerated. The only letter
Table 2 Serious and fatal complications of exercise and pharmacologic cardiac stress testing (rate of observed and reported events








Any serious complication 0.1–3.46 2.988 0.714–2.6 0.97 Case reports NR
Death 0–0.25 Case reports 0.5 Case reports Case reports NR
VFib/VTach 0–25.7 0.6–1.35 NR NR NR NR
Acute MI 0.038 0.3–3.0 1.0 0.108 Case reports NR
Cardiac rupture Unknown Case reports NR NR NR NR
High degree AVB or asystole Unknown NR Case reports Case reports Case reports NR
Bronchospasm Unknown NR 1.5 0.76 Case reports NR
Stroke/TIA Unknown Case reports NR NR Case reports NR
AFib Unknown 5–40 NR NR Case reports NR
Seizure Unknown Case reports NR 1.5 Case reports NR
CIN NR NR NR NR NR NR
NSF NR NR NR NR NR 0–18%a
Radiation-Induced Cancer NR NR NR (theoretical) NR (theoretical) NR (theoretical) NR
AVB atrioventricular block, AFib atrial fibrillation, CIN contrast induced nephropathy, MI myocardial infarction, NSF nephrogenic systemic fibrosis, NR not reported,
TIA transient ischemic attack, VFib ventricular fibrillation, VTach ventricular tachycardia
aRate of NSF is negligible if not zero in the current era of not administering gadolinium if the estimated glomerular filtration rate is < 30 ml/min/1.74 m2
References for entries are reported in Dilsizian et al. [3]
Table 3 Aminophylline and Alternative Vasodilator stress reversal agents
Reversal Agent HCPCS Code Formulation Cost per unit dosea Recommended dose Additional recommendations
IV Aminophylline J0280 250mg in 10mL vial $9.92 50–125mg; slow
manual injection
May repeat additional 50–125mg
as needed if the initial dose has
not completely eliminated symptoms
IV Theophylline J2810 400mg in 500mL bag $3.50 50mg; slow manual
injection (over 1 min)
May repeat additional 50 mg if needed
IV Caffeine Citrate J0706 60 mg in 3 mL vial $6.05 60mg diluted in 25 cc
D5W; infused over 3–5 min
May repeat an infusion (30–60 mg)
if neededb
PO Caffeine – Caffeinated beverage – Estimated 60–160mg;
given as a regular coffee,
tea or caffeinated beveragec
Consider switching to IV Aminophylline
or IV Caffeine if lack of complete
resolution of symptoms achieved
HCPCS code The Healthcare Common Procedure Coding System (HCPCS) is a collection of codes that represent procedures, supplies, products and services which
may be provided to Medicare beneficiaries and to individuals enrolled in private health insurance programs. IV intravenous; mg milligram; PO oral; aCost data
provided by Pete Antonopoulos, PharmD, Cook County Health, October 15, 2018. bNo definitive evidence available regarding the repeat dose. cMost regular
coffees contain over 100 mg of caffeine; see data from Center for Science in the Public Interest data in Appendix 1 of 2016 ASNC Stress Protocols and Tracers
guidelines.[1] For example, a 16 fluid ounce Starbucks Grande has 330 mg, and a Keurig Coffee K-Cup which makes 8 oz of coffee has 75–150 mg. A 12 oz Diet
Coke has 47 mg; the Food and Drug Administration limit for cola and pepper soft drinks is 71mg per 12 oz.
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addressing this delivery method[18] did not report rates of
successful reversal of side effects or ischemic electrocar-
diographic changes, or the need for additional pharma
cologic reversal, and thus this approach still warrants for-
mal investigation. Direct IV injection of caffeine over a
shorter period of 30 to 60 s has not been studied to date.
Data regarding use of the alternative reversal agents is
summarized in Table 3. Of note, calculation of the IV or
oral caffeine dose comparable with an index dose of IV
aminophylline is challenging and not always feasible [12].
Finally, adding low-level exercise to vasodilator stress in
patients undergoing MPI (except patients with left bundle
branch block or right ventricular pacemaker), may
minimize some adverse reactions during and after the
vasodilator stress, but cannot completely eliminate these
negative effects [17]. Thus, reversal agents should be avail-
able in any stress laboratory performing vasodilator stress
testing and medical staff should be familiar and efficient
in recognizing SISE.
While reversal of the adverse effects is an important
part of safety protocols in the modern nuclear cardiology
or cardiac magnetic resonance laboratory, vasodilator
induced coronary steal and ischemia in patients with
coronary disease may produce angina, ischemic electro
cardiographic changes and/or ischemic arrhythmias.
Therefore, approved advanced cardiac life support
(ACLS) protocols, in addition to reversal agent adminis-
tration, must be readily available. Similar to ischemic
complications, non-cardiac severe adverse reactions,
such as severe wheezing, headache or seizures, require
availability of a full spectrum of emergent therapeutic
measures targeting these symptoms.
In the absence of comparative effectiveness studies,
given the chemical similarities (aminophylline is a mixture
of theophylline and ethylenediamine), the panel recom-
mends the use of IV theophylline as a first choice reversal
agent where possible when aminophylline is not available.
However, shortages of these drugs have been noted in
tandem, so when neither is available, IV caffeine should be
used for reversal of SISE.
Summary
Vasodilator stress related adverse reactions and complica-
tions may require implementation of a reversal procedure
in approximately 1–10% of patients. There is no definitive
published evidence showing any significant clinical benefit
of the preventive use of vasodilator stress reversal in
patients undergoing vasodilator stress MPI who are
asymptomatic. Patients should be routinely advised prior
to testing that rapid, safe and effective reversal of any
adverse effects of vasodilator stress testing is immediately
available. Based on the available evidence, several effective
and safe options for reversal of vasodilator stress-related
complications/adverse reactions are available. These include
IV aminophylline, theophylline, and caffeine. Theophylline
and caffeine can be substituted for aminophylline in the
nuclear cardiology or cardiac magnetic resonance practice
in the event of a shortage of IV aminophylline. Moreover,
oral caffeine is typically effective in mild cases of vasodilator
stress-associated adverse reactions for most patients. These
reversal agents have been shown to be safe and effective.
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